SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the

LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for

VIZZ is now available for those who qualify through a convenient telehealth platform in addition to

SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasda

LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “

Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set

LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript

LENZ Therapeutics NASDAQ: LENZ reported first-quarter 2026 results that showed continued prescriptio

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.32 per share versus the Zacks Co

Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 4

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submis

LENZ Therapeutics offers a very high-risk but even higher-reward opportunity with Vizz, its aceclidi

It's recently commercialized VIZZ hasn't generated much fizz with the market yet. It has high hopes

Abeona Therapeutics (NASDAQ: ABEO - Get Free Report) and LENZ Therapeutics (NASDAQ: LENZ - Get Free

LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript

Lenz missed on sales and missed on Q4 earnings this morning. The vision drugs company said it's on p

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.16 per share versus the Zacks Co